2.0 mg intravitreal aflibercept
DRCR.net Protocol T
Phase 3 small_molecule completed
Quick answer
2.0 mg intravitreal aflibercept for Diabetic Macular Edema is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Diabetic Macular Edema
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed